Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.03
NAS:ENDP's Cash to Debt is ranked lower than
97% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. NAS:ENDP: 0.03 )
Ranked among companies with meaningful Cash to Debt only.
NAS:ENDP' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.52 Max: No Debt
Current: 0.03
Equity to Asset 0.32
NAS:ENDP's Equity to Asset is ranked lower than
86% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. NAS:ENDP: 0.32 )
Ranked among companies with meaningful Equity to Asset only.
NAS:ENDP' s Equity to Asset Range Over the Past 10 Years
Min: 0.08  Med: 0.56 Max: 0.77
Current: 0.32
0.08
0.77
F-Score: 3
Z-Score: -0.06
M-Score: -2.63
WACC vs ROIC
6.58%
-3.50%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) -30.47
NAS:ENDP's Operating margin (%) is ranked lower than
84% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.49 vs. NAS:ENDP: -30.47 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:ENDP' s Operating margin (%) Range Over the Past 10 Years
Min: -31.17  Med: 24.92 Max: 38.19
Current: -30.47
-31.17
38.19
Net-margin (%) -44.15
NAS:ENDP's Net-margin (%) is ranked lower than
86% of the 706 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.03 vs. NAS:ENDP: -44.15 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:ENDP' s Net-margin (%) Range Over the Past 10 Years
Min: -26.19  Med: 15.12 Max: 24.67
Current: -44.15
-26.19
24.67
ROE (%) -27.17
NAS:ENDP's ROE (%) is ranked lower than
82% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. NAS:ENDP: -27.17 )
Ranked among companies with meaningful ROE (%) only.
NAS:ENDP' s ROE (%) Range Over the Past 10 Years
Min: -85.73  Med: 15.31 Max: 26.98
Current: -27.17
-85.73
26.98
ROA (%) -8.65
NAS:ENDP's ROA (%) is ranked lower than
78% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.72 vs. NAS:ENDP: -8.65 )
Ranked among companies with meaningful ROA (%) only.
NAS:ENDP' s ROA (%) Range Over the Past 10 Years
Min: -10.68  Med: 9.03 Max: 17.45
Current: -8.65
-10.68
17.45
ROC (Joel Greenblatt) (%) -96.89
NAS:ENDP's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.14 vs. NAS:ENDP: -96.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:ENDP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -125.42  Med: 235.93 Max: 753.26
Current: -96.89
-125.42
753.26
Revenue Growth (3Y)(%) -4.60
NAS:ENDP's Revenue Growth (3Y)(%) is ranked lower than
77% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. NAS:ENDP: -4.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:ENDP' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -4.6  Med: 21.00 Max: 30.3
Current: -4.6
-4.6
30.3
» NAS:ENDP's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ENDP Guru Trades in Q2 2015

Joel Greenblatt 11,516 sh (New)
Paul Tudor Jones 50,589 sh (New)
Jim Simons 183,760 sh (New)
Kyle Bass 24,779 sh (New)
Diamond Hill Capital 12,850 sh (New)
Louis Moore Bacon 685,413 sh (+1691.37%)
Larry Robbins 8,837,703 sh (+29.10%)
Wallace Weitz 961,135 sh (+28.57%)
Pioneer Investments 562,603 sh (+9.67%)
Steve Mandel 3,570,117 sh (+9.17%)
RS Investment Management 375,286 sh (+5.20%)
George Soros 2,299,781 sh (+3.73%)
Mario Gabelli 15,050 sh (+2.73%)
Dodge & Cox 2,560 sh (unchged)
John Griffin 4,200,000 sh (-14.96%)
» More
Q3 2015

ENDP Guru Trades in Q3 2015

John Paulson 1,710,000 sh (New)
Steven Cohen 400 sh (New)
Kyle Bass 52,634 sh (+112.41%)
Diamond Hill Capital 20,050 sh (+56.03%)
RS Investment Management 419,901 sh (+11.89%)
Mario Gabelli 16,350 sh (+8.64%)
Steve Mandel 3,859,641 sh (+8.11%)
Wallace Weitz 972,478 sh (+1.18%)
John Griffin 4,200,000 sh (unchged)
Joel Greenblatt Sold Out
Louis Moore Bacon Sold Out
Jim Simons Sold Out
Dodge & Cox Sold Out
Pioneer Investments 541,141 sh (-3.81%)
George Soros 2,016,984 sh (-12.30%)
Larry Robbins 6,944,273 sh (-21.42%)
Paul Tudor Jones 22,703 sh (-55.12%)
» More
Q4 2015

ENDP Guru Trades in Q4 2015

Louis Moore Bacon 20,751 sh (New)
Andreas Halvorsen 4,520,954 sh (New)
Steven Cohen 396,500 sh (+99025.00%)
John Paulson 3,302,200 sh (+93.11%)
RS Investment Management 543,593 sh (+29.46%)
George Soros 2,163,967 sh (+7.29%)
Steve Mandel Sold Out
Larry Robbins Sold Out
Kyle Bass Sold Out
Mario Gabelli 14,700 sh (-10.09%)
Wallace Weitz 684,923 sh (-29.57%)
Diamond Hill Capital 13,567 sh (-32.33%)
John Griffin 2,050,000 sh (-51.19%)
Pioneer Investments 229,122 sh (-57.66%)
Paul Tudor Jones 8,009 sh (-64.72%)
» More
Q1 2016

ENDP Guru Trades in Q1 2016

David Dreman 792 sh (New)
Jim Simons 569,260 sh (New)
Paul Tudor Jones 64,148 sh (+700.95%)
John Paulson 9,517,500 sh (+188.22%)
RS Investment Management 1,368,053 sh (+151.67%)
Wallace Weitz 968,093 sh (+41.34%)
George Soros 103,200 sh (unchged)
John Paulson 119,900 sh (unchged)
Mario Gabelli Sold Out
George Soros Sold Out
John Griffin Sold Out
Louis Moore Bacon Sold Out
Andreas Halvorsen 4,468,744 sh (-1.15%)
Diamond Hill Capital 12,443 sh (-8.28%)
Pioneer Investments 140,434 sh (-38.71%)
Steven Cohen 228,000 sh (-42.50%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ENDP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:XTER:SAZ, TSE:4516, SZSE:000028, SZSE:000999, SZSE:000623 » details
Traded in other countries:ENL.Canada, EO7.Germany,
Endo International PLC is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products as well as medical devices.

Endo International PLC was incorporated in Ireland on October 31, 2013. It is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products as well as medical devices. Its current portfolio is associated with a set of therapeutic areas including, Allergy Immunotherapy, Central Precocious Puberty, Dermatology, Insomnia, Pain, Pelvic Health, Urology and Women's Health.

Ratios

vs
industry
vs
history
Forward P/E 2.76
ENDP's Forward P/E is ranked higher than
96% of the 73 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.02 vs. ENDP: 2.76 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 0.58
ENDP's P/B is ranked higher than
94% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. ENDP: 0.58 )
Ranked among companies with meaningful P/B only.
ENDP' s P/B Range Over the Past 10 Years
Min: 0.53  Med: 2.76 Max: 17.5
Current: 0.58
0.53
17.5
P/S 0.89
ENDP's P/S is ranked higher than
85% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.72 vs. ENDP: 0.89 )
Ranked among companies with meaningful P/S only.
ENDP' s P/S Range Over the Past 10 Years
Min: 0.81  Med: 2.63 Max: 6.1
Current: 0.89
0.81
6.1
POCF 26.56
ENDP's POCF is ranked lower than
68% of the 254 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.49 vs. ENDP: 26.56 )
Ranked among companies with meaningful POCF only.
ENDP' s POCF Range Over the Past 10 Years
Min: 4.02  Med: 9.89 Max: 212.54
Current: 26.56
4.02
212.54
EV-to-EBIT -9.75
ENDP's EV-to-EBIT is ranked lower than
99.99% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.53 vs. ENDP: -9.75 )
Ranked among companies with meaningful EV-to-EBIT only.
ENDP' s EV-to-EBIT Range Over the Past 10 Years
Min: -92.2  Med: 7.30 Max: 27.5
Current: -9.75
-92.2
27.5
EV-to-EBITDA -25.74
ENDP's EV-to-EBITDA is ranked lower than
99.99% of the 553 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.05 vs. ENDP: -25.74 )
Ranked among companies with meaningful EV-to-EBITDA only.
ENDP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -105.5  Med: 7.10 Max: 252.9
Current: -25.74
-105.5
252.9
Current Ratio 0.96
ENDP's Current Ratio is ranked lower than
89% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. ENDP: 0.96 )
Ranked among companies with meaningful Current Ratio only.
ENDP' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 1.92 Max: 3.55
Current: 0.96
0.96
3.55
Quick Ratio 0.75
ENDP's Quick Ratio is ranked lower than
88% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. ENDP: 0.75 )
Ranked among companies with meaningful Quick Ratio only.
ENDP' s Quick Ratio Range Over the Past 10 Years
Min: 0.75  Med: 1.71 Max: 3.34
Current: 0.75
0.75
3.34
Days Inventory 110.38
ENDP's Days Inventory is ranked higher than
52% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.44 vs. ENDP: 110.38 )
Ranked among companies with meaningful Days Inventory only.
ENDP' s Days Inventory Range Over the Past 10 Years
Min: 75.59  Med: 102.43 Max: 128.53
Current: 110.38
75.59
128.53
Days Sales Outstanding 90.04
ENDP's Days Sales Outstanding is ranked lower than
60% of the 613 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.15 vs. ENDP: 90.04 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENDP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.33  Med: 99.64 Max: 156.64
Current: 90.04
71.33
156.64
Days Payable 46.51
ENDP's Days Payable is ranked lower than
73% of the 584 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.00 vs. ENDP: 46.51 )
Ranked among companies with meaningful Days Payable only.
ENDP' s Days Payable Range Over the Past 10 Years
Min: 80.36  Med: 172.85 Max: 300.35
Current: 46.51
80.36
300.35

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.44
ENDP's Price/Projected FCF is ranked higher than
96% of the 304 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.58 vs. ENDP: 0.44 )
Ranked among companies with meaningful Price/Projected FCF only.
ENDP' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.41  Med: 0.73 Max: 2.17
Current: 0.44
0.41
2.17
Price/Median PS Value 0.34
ENDP's Price/Median PS Value is ranked higher than
95% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.12 vs. ENDP: 0.34 )
Ranked among companies with meaningful Price/Median PS Value only.
ENDP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.39  Med: 1.21 Max: 3.15
Current: 0.34
0.39
3.15
Earnings Yield (Greenblatt) (%) -10.30
ENDP's Earnings Yield (Greenblatt) (%) is ranked lower than
84% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. ENDP: -10.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ENDP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.6  Med: 9.20 Max: 26.8
Current: -10.3
3.6
26.8
Forward Rate of Return (Yacktman) (%) 37.52
ENDP's Forward Rate of Return (Yacktman) (%) is ranked higher than
92% of the 323 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.27 vs. ENDP: 37.52 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ENDP' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 3.3  Med: 30.55 Max: 63.3
Current: 37.52
3.3
63.3

More Statistics

Revenue (TTM) (Mil) $3,518
EPS (TTM) $ -7.50
Beta0.95
Short Percentage of Float4.62%
52-Week Range $12.56 - 88.54
Shares Outstanding (Mil)222.66

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 4,082 4,351 4,554
EPS ($) 4.97 5.57 6.23
EPS without NRI ($) 4.97 5.57 6.23
EPS Growth Rate
(3Y to 5Y Estimate)
7.85%
» More Articles for NAS:ENDP

Headlines

Articles On GuruFocus.com
Wally Weitz Sells Stake in Endo International, a Stock Down 75% May 26 2016 
The PBM Empire Strikes Back May 10 2016 
Wallace Weitz Comments on Endo International Apr 22 2016 
Weitz Partners Value Fund 1st Quarter 2016 Commentary Apr 22 2016 
Weitz Value Funds' 1st Quarter 2016 Commentry Apr 22 2016 
John Paulson Raises Stake in Valeant, Teva Pharmaceutical Mar 18 2016 
Steve Mandel Sells Allergan, DaVita During 4th Quarter Feb 29 2016 
Wallace Weitz Exits Stake in Alphabet, Cuts Oracle Feb 18 2016 
Wallace Weitz Comments on Endo International Jan 22 2016 
Wallace Weitz Offers Rare Intra-Quarter Portfolio Update Dec 21 2015 

More From Other Websites
Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Endo... May 29 2016
Endo Could Be the Next Activist Target in Generics May 28 2016
ENDO SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds... May 27 2016
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation of Claims Against Endo... May 27 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Endo International plc of a Class... May 27 2016
Endo could be the next activist target in generics May 27 2016
Wally Weitz Drops Falling Drug Stock Endo but Sees 'Upside Potential' May 26 2016
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Endo... May 25 2016
Endo Employees Participate in 3rd Annual "Endo Gives" Day of Volunteering, Giving Back to Local... May 25 2016
Endo Employees Participate in 3rd Annual "Endo Gives" Day of Volunteering, Giving Back to Local... May 25 2016
Trader extends bullish position in Endo May 23 2016
Top trades for the 2nd half: HBI, QCOM, ENDP & DE May 20 2016
Pelvic mesh maker AMS claims women were lured into needless surgeries May 20 2016
Specialty Pharma Stocks are Cheap…But Only Some are Worth Buying May 20 2016
Billionaire John Paulson Boosts Stakes in Endo Pharmaceuticals, Akorn; Plus Top Three New Positions May 20 2016
Interest Rate Concerns Lead to Market Losses: How Did XLV React? May 19 2016
ETF’s with exposure to Endo International Plc : May 19, 2016 May 18 2016
Endo International Plc :ENDP-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Claims Against Endo International... May 17 2016
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Endo International... May 17 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)